Bronte Capital Management Pty Ltd. Acquires 3,979 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Bronte Capital Management Pty Ltd. lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 145,421 shares of the biopharmaceutical company’s stock after buying an additional 3,979 shares during the period. Regeneron Pharmaceuticals accounts for approximately 12.2% of Bronte Capital Management Pty Ltd.’s holdings, making the stock its 3rd biggest position. Bronte Capital Management Pty Ltd.’s holdings in Regeneron Pharmaceuticals were worth $127,722,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Annis Gardner Whiting Capital Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $26,000. Fortitude Family Office LLC acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $31,000. MCF Advisors LLC lifted its stake in Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 12 shares during the last quarter. Criterion Capital Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at $37,000. Finally, Bruce G. Allen Investments LLC bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $40,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 1.3 %

Shares of REGN traded up $12.24 during midday trading on Thursday, hitting $968.00. The stock had a trading volume of 281,944 shares, compared to its average volume of 493,490. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $998.33. The business has a 50-day simple moving average of $942.03 and a two-hundred day simple moving average of $899.83. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. The firm has a market cap of $106.25 billion, a P/E ratio of 28.60, a price-to-earnings-growth ratio of 2.74 and a beta of 0.17.

Insider Buying and Selling

In other news, EVP Joseph J. Larosa sold 1,000 shares of the stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $967.65, for a total value of $967,650.00. Following the completion of the sale, the executive vice president now owns 37,543 shares in the company, valued at $36,328,483.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Joseph J. Larosa sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $967.65, for a total transaction of $967,650.00. Following the completion of the sale, the executive vice president now directly owns 37,543 shares in the company, valued at $36,328,483.95. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $982.05, for a total transaction of $98,205.00. Following the completion of the transaction, the director now owns 18,282 shares in the company, valued at approximately $17,953,838.10. The disclosure for this sale can be found here. In the last 90 days, insiders sold 8,095 shares of company stock valued at $7,779,766. Company insiders own 8.83% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. TD Cowen lifted their price objective on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. UBS Group boosted their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. Sanford C. Bernstein initiated coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price target for the company. Truist Financial reaffirmed a “buy” rating and issued a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Finally, Morgan Stanley raised their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research note on Wednesday, March 13th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $981.71.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.